GeneDx Holdings Corp (NASDAQ:WGS) is one of the top 10 healthcare AI stocks to buy according to hedge funds.
Guggenheim analyst Subbu Nambi has raised the price target for GeneDx Holdings Corp from $88.00 to $115.00, reinforcing a bullish stance on the company’s long-term trajectory. The “Buy” rating remains unchanged, signaling confidence in GeneDx’s market position and its potential to capture a growing share of the precision medicine space.
A modern office space where the team is engaging in business development and management services.
GeneDx, known for its deep expertise in rare disease genomics and next-generation sequencing, is emerging as a leader in healthcare innovation. The company blends advanced bioinformatics with clinical expertise to help physicians diagnose complex, genetically driven conditions more efficiently. Its platform leverages massive datasets and machine learning algorithms to interpret whole-genome and exome sequencing, placing it squarely in the center of the healthcare AI movement.
The price target hike reflects Guggenheim’s view that GeneDx is well-positioned to benefit from the increasing demand for personalized medicine and the broader integration of data-driven tools in clinical care. As health systems and biopharma partners seek faster, more accurate diagnostic solutions, GeneDx’s technology and scalable infrastructure make it a critical player in the shift toward AI-enabled healthcare. With momentum building across both clinical and commercial channels, the company appears to be gaining traction at a pivotal time for genomic medicine. The revised valuation underscores growing investor recognition of GeneDx’s role in transforming how rare and complex diseases are diagnosed and managed.
READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now.
Hedge Fund Resource Center